Humana Inc.

UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?

UnitedHealth (UNH) has surged 38.8% over six months as medical-cost pressures ease and confidence improves. The company's medical care ratio fell to 85.3%, medical costs declined 2%, and 2026 EPS estimates rose 21.2% to $19.82. Despite the rally, UNH trades below its five-year median valuation and analyst price targets, suggesting further upside potential. The stock carries a Zacks Rank #2 (Buy) rating.